New pill shows promise for rare lung cancer mutation in early trial
Disease control
Completed
This early-phase study tests a new oral drug, furmonertinib, in 30 people with advanced non-small cell lung cancer that has a specific EGFR exon 20 insertion mutation. Some participants have already tried other treatments, while others are newly diagnosed. The goal is to see if t…
Phase: PHASE1 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC